Biomarkers of systemic inflammatory response in patients with tuberculosis, combined with HIV infection Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016
Study of inflammatory markers in sputum positive patients of pulmonary tuberculosis and its response to anti-tubercular treatment Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016
C-reactive protein and pulmonary tuberculosis: What correlation with disease severity Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Individual dynamic of inflammatory markers as indicators of COPD treatment effectiveness Source: International Congress 2014 – COPD: points to ponder Year: 2014
The change in serum Ca 19-9 levels according to treatment responses in pulmonary nontuberculous mycobacterial disease Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology Year: 2015
Novel biomarker more strongly associated with tuberculosis treatment outcome than conventional or genotypic methods Source: International Congress 2015 – Science and biomarkers in TB Year: 2015
Efficacy of IP-10 as a biomarker for monitoring tuberculosis therapy Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013
Association of serum cytokines with pulmonary tuberculosis treatment outcomes Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014
Biomarkers and VAP: results and perspectives Source: Eur Respir Mon 2011; 53: 24-35 Year: 2011
Prediction of complications after pneumonectomy in patients with pulmonary tuberculosis Source: International Congress 2015 – Surgery and lung cancer: results and complications Year: 2015
Rapid monitoring of tuberculosis treatment response: A multi-centre study Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment Year: 2016
Serum cytokines level can differentiate active pulmonary tuberculosis from latent TB Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Clinical evaluation of several biomarkers including IFN-γ for the diagnosis of tuberculosis infection Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016
Risk factors and clinical outcomes of delayed smear conversion in smear positive pulmonary tuberculosis Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Impact of diabetes mellitus on clinical parameters and treatment outcomes of diagnosed pulmonary tuberculosis patients Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
Risk factors for active tuberculosis in patients with inflammatory bowel disease: A case-control study Source: International Congress 2015 – Latent TB infection and screening Year: 2015
Identification of novel tuberculosis diagnostic biomarkers in plasma and saliva Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016
Asthma-associated factors - Potential predictive markers for patients stratification, personalized treatments and prevention Source: International Congress 2016 – Asthma points to ponder Year: 2016
Efficacy and safety of modified anti-tubercular treatment(ATT) regimens in treatment of tuberculosis(TB) in patients with underlying chronic liver disease(CLD) Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Relation of plasma osteopontin levels with the clinical course in patients with COPD Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014